codeine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	725	76-57-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: codeine phosphate anhydrous codeine anhydrous codeine monohydrate codeine (-)-Codeine morphine monomethyl ether methylmorphine codeine phosphate codeine sulfate codeine phosphate hydrate codeine polistirex N-Methylmorphine	An opioid analgesic related to MORPHINE but with less potent analgesic properties and mild sedative effects. It also acts centrally to suppress cough. Molecular weight: 299.37 Formula: C18H21NO3 CLOGP: 0.98 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 41.93 ALOGS: -2.72 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

codeine phosphate anhydrous
codeine anhydrous
codeine monohydrate
codeine
(-)-Codeine
morphine monomethyl ether
methylmorphine
codeine phosphate
codeine sulfate
codeine phosphate hydrate
codeine polistirex
N-Methylmorphine

An opioid analgesic related to MORPHINE but with less potent analgesic properties and mild sedative effects. It also acts centrally to suppress cough.

Molecular weight: 299.37
Formula: C18H21NO3
CLOGP: 0.98
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 41.93
ALOGS: -2.72
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	435 mg/mL	Benet LZ, Broccatelli F, Oprea TI
t_half (Half-life)	4 hours	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	3.50 L/kg	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	20.04 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
CL (Clearance)	15 mL/min/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
fu (Fraction unbound in plasma)	0.70 %	Lombardo F, Berellini G, Obach RS
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Jan. 21, 1952	FDA	ANI PHARMS

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	5587.83	12.42	4657	116967	306030	63061368
Blood parathyroid hormone decreased	512.25	12.42	286	121338	9505	63357893
Panniculitis	474.73	12.42	287	121337	11098	63356300
Granuloma skin	470.36	12.42	257	121367	8180	63359218
Rheumatoid arthritis	464.47	12.42	1297	120327	252522	63114876
Rheumatoid nodule	416.64	12.42	309	121315	16846	63350552
Skin necrosis	379.13	12.42	269	121355	13681	63353717
Drug intolerance	331.93	12.42	1318	120306	307343	63060055
Hypercalcaemia	288.31	12.42	312	121312	28010	63339388
Toxicity to various agents	277.11	12.42	1070	120554	246180	63121218

Showing 1 to 10 of 465 entries

Previous1 2 3 4 5…47Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	2002.14	12.87	1198	30850	97898	34826985
Toxicity to various agents	1750.79	12.87	1448	30600	198914	34725969
Drug hypersensitivity	527.35	12.87	497	31551	80032	34844851
Substance abuse	370.02	12.87	167	31881	7474	34917409
Poisoning	235.14	12.87	144	31904	12082	34912801
Overdose	231.94	12.87	347	31701	90712	34834171
Intentional product misuse	218.30	12.87	238	31810	45373	34879510
Drug dependence	178.50	12.87	160	31888	24057	34900826
Asphyxia	177.88	12.87	98	31950	6737	34918146
Depressed level of consciousness	139.76	12.87	184	31864	42657	34882226

Showing 1 to 10 of 149 entries

Previous1 2 3 4 5…15Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	4273.05	11.70	3734	131303	295182	79314169
Drug abuse	1479.06	11.70	1590	133447	161101	79448250
Toxicity to various agents	1272.85	11.70	2431	132606	419109	79190242
Blood parathyroid hormone decreased	514.53	11.70	282	134755	10254	79599097
Panniculitis	477.56	11.70	284	134753	12087	79597264
Granuloma skin	474.28	11.70	255	134782	8919	79600432
Rheumatoid arthritis	434.12	11.70	1036	134001	207434	79401917
Rheumatoid nodule	432.30	11.70	303	134734	17135	79592216
Drug intolerance	367.26	11.70	1131	133906	262988	79346363
Substance abuse	353.37	11.70	221	134816	10305	79599046

Showing 1 to 10 of 547 entries

Previous1 2 3 4 5…55Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N02AA59	NERVOUS SYSTEM ANALGESICS OPIOIDS Natural opium alkaloids
ATC	N02AA79	NERVOUS SYSTEM ANALGESICS OPIOIDS Natural opium alkaloids
ATC	N02AJ06	NERVOUS SYSTEM ANALGESICS OPIOIDS Opioids in combination with non-opioid analgesics
ATC	N02AJ07	NERVOUS SYSTEM ANALGESICS OPIOIDS Opioids in combination with non-opioid analgesics
ATC	N02AJ08	NERVOUS SYSTEM ANALGESICS OPIOIDS Opioids in combination with non-opioid analgesics
ATC	N02AJ09	NERVOUS SYSTEM ANALGESICS OPIOIDS Opioids in combination with non-opioid analgesics
ATC	R05DA04	RESPIRATORY SYSTEM COUGH AND COLD PREPARATIONS COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS Opium alkaloids and derivatives
CHEBI has role	CHEBI:35482	narcotic analgesic
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:50266	Prodrugs

Showing 1 to 10 of 25 entries

Previous1 2 3Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Pain	indication	22253000
Cough	indication	49727002
Allergic rhinitis	indication	61582004
Nasal discharge	indication	64531003
Nasal congestion	indication	68235000
Rhinitis	indication	70076002	DOID:4483
Sneezing	indication	76067001
Common cold	indication	82272006	DOID:10459
Headache disorder	indication	230461009
Sore throat symptom	indication	267102003

Showing 1 to 10 of 149 entries

Previous1 2 3 4 5…15Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.38	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
8MG;54.3MG	TUXARIN ER	MAINPOINTE	N206323	June 22, 2015	RX	TABLET, EXTENDED RELEASE	ORAL	9066942	Jan. 3, 2032	TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS

Showing 1 to 1 of 1 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN	AGONIST	Ki	6.14	CHEMBL	CHEMBL
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN	AGONIST	Ki	4.59	CHEMBL
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN	AGONIST	Ki	4.28	CHEMBL
Opioid receptor	GPCR		OPRD_RAT OPRM_RAT OPRK_RAT SGMR1_RAT		IC50	8	CHEMBL

Showing 1 to 4 of 4 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
001550	NDDF
001551	NDDF
001552	NDDF
001553	NDDF
005189	NDDF
1268991009	SNOMEDCT_US
1476002	SNOMEDCT_US
1545976	RXNORM
1673	IUPHAR_LIGAND_ID
261000	SNOMEDCT_US

Showing 1 to 10 of 43 entries

Previous1 2 3 4 5Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Acetaminophen and Codeine Phosphate	HUMAN PRESCRIPTION DRUG LABEL	2	0093-0050	TABLET	15 mg	ORAL	ANDA	27 sections
Acetaminophen and Codeine Phosphate	HUMAN PRESCRIPTION DRUG LABEL	2	0093-0050	TABLET	15 mg	ORAL	ANDA	27 sections
Acetaminophen and Codeine Phosphate	HUMAN PRESCRIPTION DRUG LABEL	2	0093-0150	TABLET	30 mg	ORAL	ANDA	27 sections
Acetaminophen and Codeine Phosphate	HUMAN PRESCRIPTION DRUG LABEL	2	0093-0150	TABLET	30 mg	ORAL	ANDA	27 sections
Acetaminophen and Codeine Phosphate	HUMAN PRESCRIPTION DRUG LABEL	2	0093-0350	TABLET	60 mg	ORAL	ANDA	27 sections
Acetaminophen and Codeine Phosphate	HUMAN PRESCRIPTION DRUG LABEL	2	0093-0350	TABLET	60 mg	ORAL	ANDA	27 sections
Acetaminophen and Codeine Phosphate	HUMAN PRESCRIPTION DRUG LABEL	2	0121-0504	SOLUTION	12 mg	ORAL	ANDA	34 sections
Acetaminophen and Codeine Phosphate	HUMAN PRESCRIPTION DRUG LABEL	2	0121-0504	SOLUTION	12 mg	ORAL	ANDA	34 sections
Acetaminophen and Codeine Phosphate	HUMAN PRESCRIPTION DRUG LABEL	2	0121-1008	SOLUTION	30 mg	ORAL	ANDA	34 sections
Acetaminophen and Codeine Phosphate	HUMAN PRESCRIPTION DRUG LABEL	2	0121-1008	SOLUTION	30 mg	ORAL	ANDA	34 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next